Biotech Startups

Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.

2 investors

ResearchHub is a platform that connects researchers, funders, and the public to facilitate open science through transparent peer review, public preregistration, and decentralized funding mechanisms. The platform uses a native token (ResearchCoin) to reward scientific work including research funding, peer review, replication, and discussion.

2 investors

Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier. The company operates in the neuroscience drug development space.

2 investors

Resilient Biotics uses microbiome genomics and data science to discover and develop non-antibiotic, precision microbial therapeutics derived from commensal microbial communities, aimed at preventing respiratory infectious diseases.

2 investors

Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings. The Swiss company's IVD product is intended for clinical microbiology use with bacterial pathogens.

2 investors

ResNovas Therapeutics appears to be a therapeutics company, but the page provides no usable details about its products, technology, or market.

2 investors

Resonant develops antibody-based therapeutics for oncology using deep cancer biology and drug discovery expertise. The company leverages world-class antibody engineering capabilities to advance oncology drug programs.

2 investors

Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.

2 investors

Reticular provides genetic screening and embryo analysis for prospective parents, offering risk assessments for pregnancy loss, inherited diseases, and health traits to inform reproductive decisions.

2 investors

First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.

2 investors

Rev Genomics is a plant biotechnology company that develops novel plant cultivars. It serves breeders, growers, and retailers looking to differentiate in high-value markets.

2 investors

RevMed is an advanced regenerative medicine company focused on researching and developing therapeutic solutions in the regenerative medicine field. The company aims to extend human lifespan and improve health outcomes through life-centered innovation.

2 investors

RreviveMed applies artificial intelligence to metabolomics and biology to support drug discovery in the pharmaceutical and biotech sector.

2 investors

High-throughput RNA biological platform feeding a machine learning predictive engine.

2 investors

Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.

2 investors

RheaVita manufactures scalable freeze-dryer systems for pharmaceutical and vaccine development, ranging from R&D models to GMP-compliant production units. The company serves pharmaceutical and biotech manufacturers seeking to accelerate drug development and lyophilization scaling.

2 investors

Ribbon Bio develops cell-free DNA synthesis and analysis products for research and diagnostics applications. The company operates in the biotechnology and genomics sector.

2 investors

Ribolia (瑞博生物) is a pioneer in RNAi technology and small nucleic acid drug development, with research platforms covering drug delivery, chemical modification, and multi-target drug development. The company serves patients with chronic diseases including cardiovascular, metabolic, kidney, and liver conditions through its siRNA pipeline.

2 investors

RiboNova is a biopharmaceutical company developing small molecule drugs and precision medicines targeting transfer RNA for the treatment of mitochondrial disease. The company operates a proprietary drug discovery platform with a Phase-2 ready candidate in its pipeline.

2 investors

Ricovr Healthcare develops point-of-care diagnostic technology for fast, on-site testing aimed at improving workplace safety and healthcare. The company builds medical devices in the diagnostics space.

2 investors

Rigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.

2 investors

Rise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.

2 investors

River Biomedics develops human cardiac in vitro models used for drug target and compound validation, building a pipeline of cardiac therapies. It focuses on treatments for cardiac diseases by targeting biological processes involved in their pathology.

2 investors

Rivia builds an AI-powered platform for clinical trials that integrates and harmonizes fragmented trial data from multiple vendors into standardized models, then applies AI agents for data quality checks, monitoring, and analysis. It serves medical and clinical operations teams running clinical trials in the life sciences and healthcare research sector.

2 investors